Search results - ORA - Oxford University Research Archive

« Previous | 1 - 10 of 21 | Next »

1

Conference item

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+

Talbot, D, Govindan, R, Cobo, M, et al.
2018-10-22

2

Conference item

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+

Govindan, R, Dols, MC, Aix, S, et al.
2017-11-07

3

Journal article

Diagnostic and management pathways for pulmonary carcinoid tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project

Mansoor, W, Ferguson, S, Ross, V, et al.
2020-02-28

4

Journal article

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Ponce Aix, S, Talbot, D, Ramaswamy, G, et al.
2020-03-31

5

Conference item

Second-line real-world treatment patterns and outcomes in patients with advanced/metastatic non-small cell lung cancer treated with first line immuno-oncology monotherapy

Talbot, D, Fish, SM, Ong, TJ, et al.
2019-09-28

6

Journal article

The development of an Australian teacher performance assessment: lessons from the international literature

Stacey, M, Talbot, D, Buchanan, J, et al.
2019-09-21

7

Journal article

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

Natale, R, Blackhall, F, Kowalski, D, et al.
2014-11-01

8

Conference item

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

Pacey, S, Blackhall, F, Garcia-Corbacho, J, et al.
2016-10-01

9

Conference item

Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial

Meyer, T, Qian, W, Valle, J, et al.
2016-10-11

10

Journal article

The rate of neutropenic sepsis (NS) and other haematological toxicities in patients with advanced non small cell lung cancer (NSCLC) treated with docetaxel in the UK NHS: REVEAL-NS

Talbot, T, Dangoor, A, Shah, R, et al.
2017-02-09

TO TOP